Skip to main content
main-content

Lung cancer

Expert opinion

08-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Targeted therapy for ALK-, RET- and MET-driven NSCLC

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

08-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Targeting HER2 and EGFR in NSCLC

Tejas Patil gives his non-small-cell lung cancer highlights for patients positive for HER2 or EGFR mutations including the DESTINY-Lung01 and ECOG-ACRIN 5162 studies (10:29).

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The TERAVOLT findings

Leora Horn reports data from the TERAVOLT registry of thoracic cancer and COVID-19 patients, focussing on the impact of types of cancer and COVID-19 therapies on outcomes (8:35).

04-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-799 trial

Salma Jabbour discusses the KEYNOTE-799 study of pembrolizumab plus concurrent chemoradiotherapy in nonresectable stage III non-small-cell lung cancer patients (6:54).

03-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The ADAURA trial

Roy Herbst discusses the ADAURA trial investigating the postoperative use of osimertinib in patients with EGFR-mutated non-small-cell lung cancer, and comments on the potential for using it in the neoadjuvant setting (4:55).

03-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Lung cancer immuno-oncology at ASCO 2020

Erin Schenk highlights some of the lung cancer immuno-oncology studies that you may have missed at the virtual 2020 ASCO Annual Meeting (8:23).

03-06-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: The ADAURA results

Lecia Sequist explains why the phase 3 trial of adjuvant osimertinib in early-stage non-small-cell lung cancer could be practice changing (5:17).

01-06-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Initial data from CCC19

Jeremy Warner provides a comprehensive overview of the findings from the first 1018 patients with cancer and COVID-19 enrolled in the CCC19 registry (14:40).

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The PrE0505 study

Patrick Forde presents the phase 2 PrE0505 trial findings for durvalumab plus chemotherapy in patients with newly diagnosed unresectable malignant pleural mesothelioma, and discusses in light of the PROMISE-meso trial of pembrolizumab in the second-line setting (6:23).

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Three-year data from CheckMate 227

Suresh Ramalingam outlines the key findings from the 3-year update of the CheckMate 227 trial of first-line nivolumab and ipilimumab in advanced non-small-cell lung cancer (6:50).

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Final analysis of KEYNOTE-189

Delvys Rodriguez-Abreu reports the final analysis of the KEYNOTE-189 trial of pembrolizumab plus chemotherapy for patients with nonsquamous non-small-cell lung cancer (4:51).

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Dual EGFR inhibition for EGFR-mutated NSCLC

Julia Rotow outlines the rationale and preliminary findings of a study of concurrent osimertinib and gefitinib for treatment-naïve EGFR-mutated non-small-cell lung cancer (6:59).

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The KEYNOTE-604 trial

Charles Rudin reports on the phase 3 KEYNOTE-604 trial of pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer, putting the findings in context of the IMpower133 and CASPIAN studies (5:01).

31-03-2020 | Lung cancer | Podcast | Audio

COVID-19 and cancer: Changing practices to meet patient needs

Thoracic oncology nurse practitioner Beth Sandy explains how the coronavirus pandemic is affecting cancer patient care and how strategies such as telemedicine are coming into their own.

18-03-2020 | Lung cancer | Podcast | Audio

COVID-19 and cancer patient care: A lung cancer specialist’s experience

Gilberto Lopes discusses the impact of the COVID-19 pandemic on the management of patients with lung cancer and outlines the measures being implemented to minimize the risk for patients.

09-10-2019 | Non-small-cell lung cancer | Editorial | Article

Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world

Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.

04-10-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: The CheckMate 227 study

Sanjay Popat brings context to the CheckMate 227 data in light of the currently available options for patients with treatment-naïve, advanced non-small-cell lung cancer, highlighting the key aspects physicians need to bear in mind when considering nivolumab­ plus ipilimumab for their patients (2:20).

03-10-2019 | Non-small-cell lung cancer | Video | Article

Expert comment: Brain metastases in lung cancer

Lizza Hendriks provides insight into two studies focusing on brain metastases in patients with non-small-cell lung cancer, the ASCEND-7 trial of ceritinib and an analysis of the genomic and epigenomic landscape of the metastases (4:26).

02-10-2019 | Non-small-cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

Ross Camidge comments on the advanced non-small-cell lung cancer research that caught his attention at the ESMO Congress 2019, including the FLAURA and CheckMate 227 overall survival data, and updates on brigatinib and lorlatinib (3:01).

01-10-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Take-home messages from the CheckMate 227 trial

Solange Peters discusses the implications of the CheckMate 227 findings for the front-line treatment of advanced non-small-cell lung cancer and outlines the key next steps (3:45).

Image Credits